An exploratory analysis based on tumor location of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tract tumors.

Demols, Anne;Borbath, Ivan;Van den Eynde, Marc;Houbiers, Ghislain;Van Laethem, Jean-Luc;et.al.
(2019) 2019 ASCO Annual Meeting I - GASTROINTESTINAL (NONCOLORECTAL) CANCER

Files

e15622.pdf
  • Open Access
  • Adobe PDF
  • 264.05 KB
Download

Details

Authors
Show more
Abstract
An exploratory analysis based on tumor location of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tract tumors.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Demols, A., Borbath, I., Van den Eynde, M., Houbiers, G., Peeters, M., Maréchal, R., Delaunoit, T., Goeminne, J. Charles., Laurent, S., Holbrechts, S., Paesmans, M., & Van Laethem, J.-L. (2019). An exploratory analysis based on tumor location of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tract tumors. Journal of Clinical Oncology, 37(15_suppl), e15622-e15622. https://doi.org/10.1200/jco.2019.37.15_suppl.e15622 (Original work published 2019)